Active Ingredient(s): Migalastat Hydrochloride
FDA Approved: * August 10, 2018
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Galafold Overview

Migalastat, sold under the brand name Galafold, is a medication for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) granted it orphan drug status in 2004,[1] and the European Commission followed in 2006.[2] The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted the drug a marketing approval under the name Galafold in May 2016.&#...

Read more Galafold Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Galafold Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Migalastat Hydrochloride
  • Capsule: 123mg, 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Galafold: (1 result)

Sorted by National Drug Code
  • 71904-100 Galafold 123 mg Oral Capsule by Amicus Therapeutics U.S., Inc.

Other drugs which contain Migalastat Hydrochloride or a similar ingredient: (1 result)